Patents by Inventor Thomas M. Folks

Thomas M. Folks has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 6136534
    Abstract: The present invention provides a method for detecting the presence of a retrovirus in a biological sample comprising the steps of: a) contacting the biological sample with an RNA template and a complementary DNA primer under conditions whereby the RNA template and the DNA primer will anneal and a DNA strand will be synthesized as an extension from the DNA primer if reverse transcriptase is present in the sample; b) amplifying the synthesized DNA; and c) detecting the amplification of the synthesized DNA, the amplification of the synthesized DNA indicating the presence of reverse transcriptase in the biological sample, thus indicating the presence of a retrovirus in the biological sample.
    Type: Grant
    Filed: July 27, 1998
    Date of Patent: October 24, 2000
    Assignee: The United States of America as represented by the Department of Health and Human Services
    Inventors: Walid Heneine, Thomas M. Folks, William M. Switzer, Shinji Yamamoto
  • Patent number: 5882912
    Abstract: The present invention comprises spumavirus isolated from humans. More specifically, the spumavirus of the present invention was isolated from humans who had exposure to nonhuman primates. Importantly, the spumavirus of the present invention or antibodies to the spumavirus can be used to detect the presence of spumavirus or antibodies in body fluids, for pathogenicity studies of related viruses, and as a vector for gene therapies.
    Type: Grant
    Filed: February 12, 1997
    Date of Patent: March 16, 1999
    Assignee: Center For Disease Control And Prevention
    Inventors: Paul A. Sandstrom, Jennifer Brown, Thomas M. Folks, Walid Heneine, William M. Switzer
  • Patent number: 5849494
    Abstract: The present invention provides a method for detecting the presence of a retrovirus in a biological sample comprising the steps of: a) contacting the biological sample with an RNA template and a complementary DNA primer under conditions whereby the RNA template and the DNA primer will anneal and a DNA strand will be synthesized as an extension from the DNA primer if reverse transcriptase is present in the sample; b) amplifying the synthesized DNA; and c) detecting the amplification of the synthesized DNA, the amplification of the synthesized DNA indicating the presence of reverse transcriptase in the biological sample, thus indicating the presence of a retrovirus in the biological sample.
    Type: Grant
    Filed: December 11, 1996
    Date of Patent: December 15, 1998
    Assignee: The United States of America as represented by the Department of Health and Human Services
    Inventors: Walid Heneine, Thomas M. Folks, William Marshall Switzer, Shinji Yamamoto
  • Patent number: 5529765
    Abstract: A rabbit model for testing anti-AIDS therapeutic agents, vaccines, and HIV-1 infection is described.
    Type: Grant
    Filed: December 7, 1992
    Date of Patent: June 25, 1996
    Assignee: The United States of America as represented by the Department of Health and Human Services
    Inventors: Thomas J. Kindt, Henrietta Kulaga, Thomas M. Folks
  • Patent number: 5459056
    Abstract: A human T cell clone containing an integrated copy of HIV in a latent state, but inducible to productive replication by an activating agent is provided. The clone of the present invention allows in vitro screening of anti-HIV drugs.
    Type: Grant
    Filed: July 29, 1992
    Date of Patent: October 17, 1995
    Assignee: The United States of America as represented by the Department of Health and Human Services
    Inventors: Douglas M. Powell, Kathleen A. Clouse, Thomas M. Folks
  • Patent number: 5256534
    Abstract: The present invention relates to a unique physiologic model of chronic human immunodeficiency virus type-1 (HIV-1) infection. In particular, the present invention relates to a chronically infected promyelocyte cell line harboring a single integrated provirus. Unlike other models of chronic infection, the cell line of the present invention remain CD4.sup.+ under normal culture conditions during which <10% of the cells constitutively express HIV-1 proteins. However, when treated with tumor necrosis factor-alpha (TNF-.alpha.), the cell line dramatically increased (>35-fold) HIV-1 expression and rapidly down-modulated surface CD4, as >95% of the cells became HIV-1.sup.+. These results with the new OM-10.
    Type: Grant
    Filed: August 9, 1991
    Date of Patent: October 26, 1993
    Assignee: The United States of America as represented by the Department of Health and Human Services
    Inventors: Salvatore T. Butera, Thomas M. Folks, Victor L. Perez
  • Patent number: 5183949
    Abstract: A rabbit model for testing anti-AIDS therapeutic agents, vaccines, and HIV-1 infection is described.
    Type: Grant
    Filed: March 15, 1989
    Date of Patent: February 2, 1993
    Assignee: The United States of America as represented by the Department of Health and Human Services
    Inventors: Thomas J. Kindt, Henrietta Kulaga, Thomas M. Folks
  • Patent number: 4752565
    Abstract: Leu-3.sup.- cells surviving infection with the AIDS retrovirus can be induced with IUdR to express infectious virus. A cellular clone (8E5), isolated by limiting dilution of a mass culture of survivor cells, was found to contain a single, integrated, defective provirus that was consitutively expressed. Although IUdR treatment of 8E5 cells failed to induce infectious virus, cocultivation with Leu-3.sup.+ generated the characteristic syncytia associated with acute AIDS retrovirus infention. The single integrated copy of proviral DNA directs the synthesis of all major viral structural proteins except p64 and p34 as monitored by immunoblotting. Diagnostic reagents and kits in accordance with the present invention are also described.
    Type: Grant
    Filed: April 7, 1986
    Date of Patent: June 21, 1988
    Assignee: The United States of America as represented by the Department of Health and Human Services
    Inventors: Thomas M. Folks, Douglas M. Powell, Malcolm A. Martin